Stock Research for SGMO

SGMO

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

SGMO Stock Chart & Research Data

The SGMO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SGMO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


SGMO Due diligence Resources & Stock Charts

The SGMO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SGMO Detailed Price Forecast - CNN Money CNN View SGMO Detailed Summary - Google Finance
Yahoo View SGMO Detailed Summary - Yahoo! Finance Zacks View SGMO Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View SGMO Trends & Analysis - Trade-Ideas Barrons View SGMO Major Holders - Barrons
NASDAQ View SGMO Call Transcripts - NASDAQ Seeking View SGMO Breaking News & Analysis - Seeking Alpha
Spotlight View SGMO Annual Report - CompanySpotlight.com OTC Report View SGMO OTC Short Report - OTCShortReport.com
TradeKing View SGMO Fundamentals - TradeKing Charts View SGMO SEC Filings - Bar Chart
WSJ View Historical Prices for SGMO - The WSJ Morningstar View Performance/Total Return for SGMO - Morningstar
MarketWatch View the Analyst Estimates for SGMO - MarketWatch CNBC View the Earnings History for SGMO - CNBC
StockMarketWatch View the SGMO Earnings - StockMarketWatch MacroAxis View SGMO Buy or Sell Recommendations - MacroAxis
Bullish View the SGMO Bullish Patterns - American Bulls Short Pains View SGMO Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View SGMO Stock Mentions - StockTwits PennyStocks View SGMO Stock Mentions - PennyStockTweets
Twitter View SGMO Stock Mentions - Twitter Invest Hub View SGMO Investment Forum News - Investor Hub
Yahoo View SGMO Stock Mentions - Yahoo! Message Board Seeking Alpha View SGMO Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for SGMO - SECform4.com Insider Cow View Insider Transactions for SGMO - Insider Cow
CNBC View SGMO Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SGMO - OTC Markets
Yahoo View Insider Transactions for SGMO - Yahoo! Finance NASDAQ View Institutional Holdings for SGMO - NASDAQ


Stock Charts

FinViz View SGMO Stock Insight & Charts - FinViz.com StockCharts View SGMO Investment Charts - StockCharts.com
BarChart View SGMO Stock Overview & Charts - BarChart Trading View View SGMO User Generated Charts - Trading View


Latest Financial News for SGMO

Why Wall Street Analysts Are Mostly Positive on CRISPR
Posted on Friday May 18, 2018

In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe. CRISPR Therapeutics plans to submit an Investigational New Drug application to the FDA for the approval of an initiation of phase 1/2 clinical trial in the US for the treatment of sickle cell disease in the second half of 2018.


Sangamo Therapeutics Stock History
Posted on Thursday May 17, 2018

After decades of research into gene editing, this biotech company could be on the cusp of developing game-changing new treatments for rare diseases.


Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease
Posted on Wednesday May 16, 2018

Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, and Sangamo Therapeutics, Inc. (SGMO) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the treatment of people with sickle cell disease. Bioverativ and Sangamo are developing BIVV003 as part of an exclusive worldwide collaboration to develop and commercialize gene-edited cell therapies for sickle cell disease and beta thalassemia.


Edited Transcript of SGMO earnings conference call or presentation 8-May-18 12:00pm GMT
Posted on Sunday May 13, 2018

Q1 2018 Sangamo Therapeutics Inc Earnings Call


Enter a stock symbol to view the stock details.